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RESULTS: Based on the literature, waste for each vial product
was 23%, including injection error (15%) and syringe/needle
dead space (8%). Among individual pens, product waste 
was highest for Humatrope 24 mg (14.3%) and lowest for
Norditropin NordiFlex 5 mg (1.0%). Equal use of vials and pens
from each manufacturer resulted in the following product waste:
Tev-Tropin 23% (vial only), Nutropin 18.2%, Humatrope
12.2%, Genotropin 5.5%, Saizen 3.8%, and Norditropin 3.0%.
Restricting use to the product with least waste (Norditropin)
resulted in a 10.5% reduction in annual patient cost from
$24,764 to $22,161 compared to a national share mix. CON-
CLUSION: Pen delivery systems result in less waste than vial and
syringe. Considering all approved delivery systems, Norditropin
resulted in the least product waste and lower annual patient cost.
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OBJECTIVES: Short stature has been shown to inﬂuence social
factors during childhood and adult life. However, limited data
exist to determine the inﬂuence of short stature on Health
Related Quality Of Life (HRQOL) due to underpowered studies
and the fact that children ﬁnd questionnaires very hard to com-
plete. The objective of this study was to characterize the inﬂu-
ence of height on social class and HRQOL for the general adult
population in UK. METHODS: The Health Survey for England
(HSE03) was commissioned by the Department of Health and
collected data during the period 2003 to 2004. HSE03 consisted
of a random population sample in England. Observations for
14,416 adults (age >18 years) were included in the analysis. The
survey involved a questionnaire-based interview followed by a
nurse visit, where measurements and blood samples were taken.
HRQOL was measured using the EQ-5D questionnaire. Social
class (I-V) were derived according to deﬁnition from UK
National Statistics. Height was converted from centimetres to
height percentiles (0%–100%) to obtain standardized scores.
RESULTS: A regression analysis showed increasing height had a
signiﬁcant inﬂuence on increasing HRQOL. The largest HRQOL
differences were observed in the shorter groups. An ANOVA
showed HRQOL for the shortest 2.5% (EQ-5D = 0.791) was
signiﬁcantly reduced (P = 0.007) compared with all other persons
(EQ-5D = 0.873). The data showed a trend towards increasing
height having an inﬂuence on number of persons in social class
I + II. However, this trend could not account for the relationship
between height and HRQOL in the shorter subgroups. CON-
CLUSIONS: Short stature negatively impacts upon HRQOL and
does this independently of social class. The impact of height on
HRQOL was largest in the shorter height subgroups. Effects of
distinct causes of short stature can not be excluded, however sta-
tistically the majority of short persons will have idiopathic short
stature.
GI DISORDERS
PGI1
IS COMBINATION THERAPY OF LAMIVUDINE WITH
INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE
MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS
B? A META-ANALYSIS OF RANDOMIZED TRIALS
Sun X1, Zhou R2, Li Y1, Zhao L3
1West China Hospital, Sichuan University, Chengdu, China, 2West
China Medical School, Chengdu, China, 3Center of Infectious
Diseases, West China Hospital, Sichuan University, Chengdu, China
OBJECTIVE: Assess comparative efﬁcacy of combination
therapy of interferon-alpha with lamivudine versus lamivudine
monotherapy for HBeAg-positive chronic hepatitis B (CHB).
METHODS: Searched MEDLINE, SCI-Expand, Current
Content Connect, Cochrane Library and Chinese Biomedical
Database to April 25, 2006, and screened reference lists of eli-
gible trials. Randomized trials were included if comparing
lamivudine plus interferon-alpha with lamivudine alone in
patients with HBeAg-positive and ALT-elevated CHB. We
recorded interventional and patient characteristics. Quality of
trials was assessed by six items based on the Cochrane recom-
mendation. We used ﬁxed and random effect model meta-analy-
sis to pool the data. Two types of interventional strategies were
available: a) lamivudine in both arms were administrated 52
weeks; and b) lamivudine was administrated 24 weeks in com-
bination arm while 52 weeks in monotherapy. We stratiﬁed trials
for analysis, and performed sensitivity analysis based on the dose
of interferon-alpha, where appropriate. RESULTS: Twenty ran-
domized trials were included. Quality was moderate in most.
Both at 24-week (for both types) and 52-week (for type b) of
treatment, loss of HBeAg (RR = 2.54 and 1.62, 95%CI =
1.91–3.37; 1.13–2.33, p = 0.000 and 0.009) and HBeAg sero-
conversion (RR = 3.12 and 1.73, 95%CI = 2.07–4.70;
1.20–2.51, p = 0.000 and 0.004) were signiﬁcantly higher in
combination than lamivudine monotherapy. Loss of HBV DNA,
loss of HBsAg and normalization of ALT were not statistically
signiﬁcant. Two strategy types were limited in follow-up data.
However, loss of HBV DNA was signiﬁcantly higher in combi-
nation group after a 26-week follow-up in both strategies; no
signiﬁcant difference was found in serological and biomedical
markers. CONCLUSIONS: It was suggested that combination
therapy might be superior to lamivudine therapy in clearing sero-
logical markers but not for virological and biomedical ones
during treatment. Further study was needed to investigate the
long-term beneﬁt of combination therapy.
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OBJECTIVES: To compare the efﬁcacy of esomeprazole with the
European licensed standard dose of PPIs for the endoscopic
healing of reﬂux oesophagitis (i.e. esomeprazole 40 mg compared
with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40
mg, and rabeprazole 20 mg). METHODS: Systematic review of
CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with reﬂux oesophagitis was
conducted in February 2005. Data on endoscopically veriﬁed
healing rates at four and eight weeks were extracted and 
